S SoftMaxx AI
Peptides · Evidence-graded entry

Matrixyl: what the cited trials of palmitoyl pentapeptides show

Pal-KTTKS (Matrixyl): a 93-woman trial. Palmitoyl pentapeptide-4 cream: a 3-arm trial, 21 women in all. Citations checked against PubMed records.

Written by SoftMaxx AI editorial · Citations checked against PubMed records · Updated 2026-10-03 · Not medically reviewed · How we grade evidence

SoftMaxx AI sells no peptides and takes no vendor money.

The verdict · strongest evidence Human RCT

Human RCT The larger of the two palmitoyl pentapeptide trials cited here tested pal-KTTKS, which its abstract calls palmitoyl pentapeptide: in a randomized, double-blind split-face trial, 93 women used a moisturizer containing it at the trial concentration (see the doses table) on one side of the face and the same moisturizer without it on the other for 12 weeks, and fine lines and wrinkles improved significantly more on the peptide side. A smaller 8-week randomized trial split 21 women in all between a palmitoyl pentapeptide-4 (PPP-4) cream, an acetylhexapeptide-3 cream and placebo, and the PPP-4 cream did better than both.[1][2]

The peptide and its sequence

Pal-KTTKS, the compound in the 93-woman trial, is a five-amino-acid peptide (Lys-Thr-Thr-Lys-Ser, KTTKS) with a fatty-acid (palmitoyl) tail, used in anti-wrinkle creams [1][3]. The KTTKS sequence comes from type I procollagen, the collagen precursor [4], and pal-KTTKS was designed as a topical agent to stimulate collagen production [1]. A 2011 review notes relatively few clinical studies of it [3].

The palmitic-acid tail makes it more stable than plain KTTKS and lets more of it into the skin, at least in mouse skin tests [5].

The smaller trial tested a palmitoyl pentapeptide-4 (PPP-4) cream; its abstract does not give the compound's amino-acid sequence [2].

Claims vs. evidence

Each popular claim, graded by the strongest study behind it. The words in quotation marks are how the claim is marketed; the text after the grade is what the studies show.

Common myths, checked

Doses used in studies (not a recommendation)

Each row comes from the cited source: a study dose, a safety-review limit or a registered trial's planned dose, as labelled. Where the abstract states no amount, the row says so. They are a record of what was reported, not dosing instructions, and nothing here says what you should take.

Studied inRouteAmount reportedHow oftenHow longnSource
Humanstopical moisturizer, split-face3 ppm pal-KTTKS in a moisturizer (the trial concentration) Study dosenot stated in abstract12 weeks93[1] 93 Caucasian women aged 35–55 with photoaged skin; double-blind, placebo-controlled, split-face
Humanstopical cream to periorbital areanot stated in abstract Study dosetwice daily8 weeks21[2] 21 Indonesian women aged 26–55 in all, split across 3 arms

Side effects and risks

Regulatory status (checked 2026-10-01 to 2026-10-03)

Report a side effect

If something went wrong after using a health product, tell a clinician. Report side effects to:

Common questions

Does Matrixyl work?

Human RCT In the larger trial cited here, 93 women used a moisturizer with pal-KTTKS on one side of the face for 12 weeks, and fine lines and wrinkles improved significantly more than with the same moisturizer without it [1]. In a smaller 8-week trial, 21 women in all were split between a palmitoyl pentapeptide-4 cream, an acetylhexapeptide-3 cream and placebo, and the palmitoyl pentapeptide-4 cream did better than both [2]. Its abstract names the peptide only as palmitoyl pentapeptide-4, without a sequence, so it may not have been pal-KTTKS, the compound PubChem lists as Matrixyl.[1][2]

Is Matrixyl a copper peptide?

Expert review We found no cited abstract that describes copper in either trial compound: pal-KTTKS is palmitoyl-lysine-threonine-threonine-lysine-serine [1], whose KTTKS sequence comes from type I procollagen [4], and the other trial names palmitoyl pentapeptide-4 [2].[3][4][1][2]

How long does Matrixyl take to work?

The pal-KTTKS trial cited here ran 12 weeks [1]. That is how long the study ran, not a promise of results.[1]

References

Every reference below was matched to its PubMed or DOI record (title checked) before publication. "Verified" means the paper exists and is the one named; what it supports is stated next to each claim.

  1. Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin. Int J Cosmet Sci (2005). PubMed 18492182 DOI
  2. Double-blind, Randomized Trial on the Effectiveness of Acetylhexapeptide-3 Cream and Palmitoyl Pentapeptide-4 Cream for Crow's Feet. J Clin Aesthet Dermatol (2023). PubMed 36909866
  3. Topically applied KTTKS: a review. Int J Cosmet Sci (2011). PubMed 21535443 DOI
  4. A pentapeptide from type I procollagen promotes extracellular matrix production. J Biol Chem (1993). PubMed 8486721 DOI
  5. Dermal Stability and In Vitro Skin Permeation of Collagen Pentapeptides (KTTKS and palmitoyl-KTTKS). Biomol Ther (Seoul) (2014). PubMed 25143811 DOI
  6. Oral and topical peptides for skin aging: systematic review and meta-analysis of randomized controlled trials. Front Med (Lausanne) (2026). PubMed 41924746 DOI

Written by SoftMaxx AI editorial · Citations checked against PubMed records · Updated 2026-10-03 · Not medically reviewed. Editorial standards · Evidence grading and update log.

Keep reading